ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

ClinicalTrials.gov ID: NCT05557591

Public ClinicalTrials.gov record NCT05557591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Study identification

NCT ID
NCT05557591
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
51 participants

Conditions and interventions

Interventions

  • BNT116 Drug
  • Cemiplimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 20, 2023
Primary completion
Jan 25, 2028
Completion
May 15, 2028
Last update posted
May 5, 2026

2023 – 2028

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
The Oncology Institute of Hope and Innovation Los Angeles California 90033
UCLA Medical Center Santa Monica California 90095
Norton Cancer Institute, Downtown Louisville Kentucky 40202
San Juan Oncology Associates Farmington New Mexico 87401
Weill Cornell Medicine New York New York 10065
FirstHealth of the Carolinas Outpatient Cancer Center Pinehurst North Carolina 28374
Millenium Research & Clinical Development Houston Texas 77090
Virginia Cancer Specialists Fairfax Virginia 22031
Northwest Medical Specialties, PLLC Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05557591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05557591 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →